Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Inclusion Criteria: Subjects will be healthy male volunteers who meet the criteria below: * Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12-lead ECG, and laboratory test results * Persons who are 20 or older and 35 or younger * Persons with body mass index (BMI) of 18.5 kg/m2 or more and 25.0 kg/m2 less * Persons who are willing to participate in this trial before study initiation and who give their written consent in accordance with the GCP (Good Clinical Practice) Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate, body temperature, and ECG) deviating from normal and of clinical relevance * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders * Prior history of jaundice * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells, or blackouts * Chronic or relevant acute infections * History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (\>24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of any drugs within 10 days prior to administration or during the trial * Participation in another trial with an investigational product within four months prior to administration or during the trial * Smoker (\>10 cigarettes, \>3 cigars or \>3 pipes/day) * Inability to refrain from smoking on trial days (during hospitalisation and end of trial) * Alcohol abuse (more than 60 g/day) * Drug abuse * Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial) * Excessive physical activities (within 1 week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to comply with dietary regimen of the trial site * A history of additional risk factors for torsades de pointe (e.g., heart failure, hypokalemia, and family history of long QT syndrome) * The use of concomitant medications that prolong the QT/corrected QT interval